Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
UNS IP HOLDINGS, LLC is handling 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units. D' AMBROSIO, THEA is the busiest examiner, responsible for 1 pending office action, which is 1 of the 2 pending office actions for the company. This distribution indicates a decentralized prosecution for the 2 pending office actions.
Because the 2 pending office actions are assigned to 2 distinct examiners in 2 distinct art units, the company must manage two separate administrative tracks. This lack of concentration means that the prosecution strategy for one action may not directly inform the other. Practitioners should prepare for independent reviews by the 2 distinct examiners, as the 2 pending office actions are handled in different art units within the Biotechnology & Pharmaceuticals field. The involvement of 2 distinct examiners suggests a diverse range of technical subject matter within the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| D' AMBROSIO, THEA | 1 | 55.5% | +56.2% |
| BUCKMASTER, MARLENE VRENI | 1 | 28.1% | +74.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16623205 | PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND FORMULATIONS THEREOF FOR TREATMENT OF SYNUCLEINOPATHIES | BUCKMASTER, MARLENE VRENI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18375709 | TAU PEPTIDE IMMUNOGEN CONSTRUCTS | D' AMBROSIO, THEA | — |
| 16623205 | PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND FORMULATIONS THEREOF FOR TREATMENT OF SYNUCLEINOPATHIES | BUCKMASTER, MARLENE VRENI | — |
| Art Unit | Apps |
|---|---|
| 1654 | 1 |
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18375709 | TAU PEPTIDE IMMUNOGEN CONSTRUCTS | D' AMBROSIO, THEA | 1654 | §103§112DP | Non-Final OA | — | Pending | Oct 02, 2023 |
| 16623205 | PEPTIDE IMMUNOGENS FROM THE C-TERMINAL END OF ALPHA-SYNUCLEIN PROTEIN AND FORMULATIONS THEREOF FOR TREATMENT OF SYNUCLEINOPATHIES | BUCKMASTER, MARLENE VRENI | 1672 | §102§103 | Non-Final OA | — | Pending | Dec 16, 2019 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNS IP HOLDINGS, LLC has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Thea D' Ambrosio has the most, with 1 of UNS IP HOLDINGS, LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
